CD274 and non-small cell lung carcinoma: Currently, immune checkpoint inhibitors (ICIs) such as programmed death-1 (PD-1)/programmed death ligand-1 (PD-L1) antibodies are standards of care for advanced NSCLC with genomic alteration.